A5070904518- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Health Systems, Economic Evaluations, Quality of Life
- Stroke Rehabilitation and Recovery
- Acute Ischemic Stroke Management
- Breast Lesions and Carcinomas
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Statistical Methods in Clinical Trials
- Cardiac Imaging and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Lymphoma Diagnosis and Treatment
- Global Health Care Issues
- Breast Implant and Reconstruction
- Cancer survivorship and care
- Cerebrovascular and Carotid Artery Diseases
- Peripheral Artery Disease Management
- Bone health and treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Health disparities and outcomes
University of Limerick
2016-2025
Breast Cancer Trials
2010-2021
University of Newcastle Australia
2010-2020
Calvary Mater Newcastle Hospital
2008-2019
University of Glasgow
1980-2018
Calvary Riverina Hospital
2018
University of Edinburgh
2004-2018
Queen Mary University of London
2009-2018
Cancer Trials Australia
1987-2018
National Health Service
2010-2018
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
<h2>ABSTRACT</h2> The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer. Further experience has supported the adequacy of tumor margins defined as ‘no ink invasive or DCIS' safety omitting axillary dissection in specific cohorts. Radiotherapy trials support irradiation regional nodes node-positive disease. Considering subdivisions within luminal disease, Panel was more concerned with...
The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and in the neoadjuvant setting than tamoxifen. We compared with tamoxifen as adjuvant steroid-hormone-receptor-positive postmenopausal women.The Breast International Group (BIG) 1-98 study randomized, phase 3, double-blind trial that five years of various endocrine therapy regimens women hormone-receptor-positive cancer: letrozole, followed by tamoxifen, letrozole. This analysis compares two groups...
Previous analyses of the Breast International Group (BIG) 1-98 four-arm study compared initial therapy with letrozole or tamoxifen including patients randomly assigned to sequential treatment whose information was censored at time change. Because this presentation may unduly reflect early events, present analysis is limited continuous arms and includes protocol-defined updated results.Four thousand nine hundred twenty-two 8,028 postmenopausal women receptor-positive breast cancer...
Abstract BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen terms disease‐free survival (DFS), time recurrence (TTR), and incidence contralateral cancer (CLBC). In current article, results efficacy update, based on a median follow‐up period 47 months, are reported along an...
Purpose To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in tamoxifen and anastrozole arms Arimidex, Tamoxifen, Alone or Combination (ATAC) Trial. Patients Methods RNA was extracted from 1,372 tumor blocks postmenopausal patients with hormone receptor–positive primary breast cancer monotherapy ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, RS calculated. Cox proportional...
Purpose We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant beyond obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, endocrine treatment) in women with early breast cancer, confirming earlier reports. The aim of this article is to determine how much contained standard immunohistochemical (IHC) markers. Patients and Methods primary cohort comprised 1,125...
Background Aromatase inhibitors eff ectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women.We assessed the effi cacy safety aromatase inhibitor anastrozole for prevention women who are at high risk disease.Methods Between Feb 2, 2003, Jan 31, 2012, we recruited aged 40-70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial.To be eligible, had to increased (judged on basis specifi c...
Initial results of the UK/ANZ DCIS (UK, Australia, and New Zealand ductal carcinoma in situ) trial suggested that radiotherapy reduced new breast events ipsilateral invasive situ (DCIS) compared with no radiotherapy, but significant effects were noted tamoxifen. Here, we report long-term this trial.Women completely locally excised recruited into a randomised 2×2 factorial tamoxifen, or both. Randomisation was independently done for each two treatments (radiotherapy tamoxifen), stratified by...
Predicting the pattern of recurrence can aid in development targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event a median follow-up 24 years from diagnosis operable breast cancer.International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 1985. Annualized hazards were estimated cancer-free interval (primary end point), disease-free survival, overall survival.For entire group,...
Objectives To investigate severe COVID-19 risk by occupational group. Methods Baseline UK Biobank data (2006–10) for England were linked to SARS-CoV-2 test results from Public Health (16 March 26 July 2020). Included participants employed or self-employed at baseline, alive and aged <65 years in 2020. Poisson regression models adjusted sequentially baseline demographic, socioeconomic, work-related, health, lifestyle-related factors assess ratios (RRs) testing positive hospital death due...
Ovarian failure is a common toxic effect of chemotherapy. Studies the use gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes.
The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women receptor-positive early breast cancer. It is unknown whether sequential treatment tamoxifen and letrozole superior to therapy alone.In this randomized, phase 3, double-blind trial of the hormone-receptor-positive cancer in women, we randomly assigned receive 5 years monotherapy, or 2 one agent followed by 3 other. We treatments monotherapy 6182 also report a...
To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-receptor (PgR) expression human epidermal growth factor 2 (HER-2) status with time to recurrence (TTR) in postmenopausal women hormone receptor-positive primary breast cancer treated anastrozole or tamoxifen as adjuvant therapy.Formalin-fixed, paraffin-embedded tumor blocks were retrospectively collected from patients monotherapy arms of Arimidex, Tamoxifen Alone Combination (ATAC) trial centrally...
BackgroundFour previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased first 10 years follow-up. We report long-term follow-up IBIS-I trial, which participants and investigators remain largely masked to treatment allocation.MethodsIn controlled premenopausal postmenopausal 35–70 age deemed be an developing were randomly assigned (1:1) receive oral 20 mg daily or matching placebo for 5 years. Patients two...